While FLI-1 has been implicated as a therapeutic target in multiple malignancies such as Ewing sarcoma, hemangioma, and squamous cell carcinoma (Zhang et al., 2024; Yasir et al., 2023; Li et al., 2022; Ben-David et al., 2022), and autoimmune diseases such as systemic sclerosis (SSc) and systemic lupus erythematosus (sLE) (He et al., 2021), our work newly positions FLI-1 as a potential therapeutic target for IBD. This evidence concerns the gene FLI1 and hemangioma.